JW SHINYAK CORPORATION Logo

JW SHINYAK CORPORATION

Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.

067290 | KO

Overview

Corporate Details

ISIN(s):
KR7067290007
LEI:
Country:
South Korea
Address:
경기도 과천시 과천대로7길 38 -, 과천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

JW Shinyak Corporation is a pharmaceutical company that operates as a specialized maker for the clinical market. The company develops, produces, and supplies high-quality specialty medicines and medical supplies, with a primary focus on the fields of dermatology, urology, and otolaryngology. Committed to research and development, JW Shinyak aims to develop innovative new drugs through advanced medical technology, including its proprietary "DC vacuum technology" and "CTP". The company's product portfolio includes treatments for conditions such as androgenic alopecia (hair loss), endocrine disorders, and various bacterial infections.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-01 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1015.4 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.2 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.7 KB
2025-03-19 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 474.4 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.9 KB
2025-02-25 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.2 KB
2025-02-25 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 95.3 KB
2025-02-25 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 96.4 KB
2025-02-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.4 KB
2025-02-07 00:00
Regulatory News Service
주식등의대량보유상황보고서(일반)
Korean 74.0 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2025-02-07 00:00
Regulatory News Service
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB

Automate Your Workflow. Get a real-time feed of all JW SHINYAK CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JW SHINYAK CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JW SHINYAK CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.